Chitosan coating of anionic liposomes containing sumatriptan succinate: a candidate for nasal administration

Sumatriptan is a routine medication in the treatment of migraine and cluster headache that is generally given by oral or parental routes. However, a substantial proportion of patients suffer severe side effects. Nasal administration is significantly effective in case of oral administration of drug gives an undesirable side effect. So, the purpose of the present study was to develop intranasal delivery systems of Sumatriptan succinate using nanoliposomes as container of a water-soluble drug and chitosan as a mucoadhesive polymer.

Liposomal formulations containing Sumatriptan as well as chitosan-coated liposomal formulations with different phospholipids and different concentrations were prepared. The formulations were evaluated for their physicochemical properties, stability and Cytotoxicity on BEAS-2B cells.

The prepared liposomal formulations coated with chitosan containing Sumatriptan had a size range of 165±9.4to 258±6.4 nm, and the surface charge of the obtained formulations was measured between 32±6 and 40±5 mV. Also, the encapsulation efficiency of the formulations was also observed between 14.2±2.7% and 19±3.4%. Based on the obtained results of physicochemical studies, liposomes F2 was also tested for stability and toxicity and showed that the F2 liposomes retained its physicochemical properties for up to 3 months. Finally, the toxicity test of the mentioned formulation showed relatively low toxicity on BEAS-2B cells.

In the presents study, stable liposomal formulations coated with chitosan containing Sumatriptan were prepared and studied. Based on the obtained, these formulations can be used in preclinical and animal studies for the nasal administration of Sumatriptan.